Corvus Pharmaceuticals (CRVS) Institutional Ownership
13F filers reported holding 83.9% of Corvus Pharmaceuticals (CRVS) shares as of Sep 30, 2026, across 175 filers.
- Held by 13F filers
- 83.9%
- Sep 30, 2026
- 13F filers
- 175
- quarter ended Sep 30, 2026
- 13F value
- $815.0M
- 70.7M shares
- Quarter's fund flow
- Mild accumulation
- 25 new · 18 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Arcara Jeffrey | Chief Business Officer | Acquired · Open-market buy | 503 | $10.37 | ↗ |
| Nov 13, 2026 | Arcara Jeffrey | Chief Business Officer | Acquired · Open-market buy | 500 | $10.71 | ↗ |
| Nov 12, 2026 | Arcara Jeffrey | Chief Business Officer | Acquired · Open-market buy | 497 | $11.12 | ↗ |
| Nov 11, 2026 | Arcara Jeffrey | Chief Business Officer | Acquired · Open-market buy | 3,000 | $11.46 | ↗ |
| Jun 11, 2026 | Moore David Scott | director | Acquired · Open-market buy | 21,700 | $11.53 | ↗ |
| Jun 11, 2026 | Moore David Scott | director | Acquired · Grant / award | 15,000Stock Option (Right to Buy) | — | ↗ |
| Jun 11, 2026 | CLARK IAN T | director | Acquired · Grant / award | 15,000Stock Option (Right to Buy) | — | ↗ |
| Jun 11, 2026 | Grais Linda S | director | Acquired · Grant / award | 15,000Stock Option (Right to Buy) | — | ↗ |
| Jun 11, 2026 | Thompson Peter A. | director | Acquired · Grant / award | 15,000Stock Option (Right to Buy) | — | ↗ |
| Jun 11, 2026 | van den Broek Richard | director | Acquired · Grant / award | 15,000Stock Option (Right to Buy) | — | ↗ |
| May 18, 2026 | MILLER RICHARD A MD | President and CEO | Acquired · Open-market buy | 5,000 | $12.05 | ↗ |
| May 18, 2026 | MILLER RICHARD A MD | President and CEO | Acquired · Open-market buy | 1,932 | $12.01 | ↗ |
| Apr 23, 2026 | Chan Andrew C. | director | Acquired · Grant / award | 30,000Stock Option (Right to Buy) | — | ↗ |
| Jan 28, 2026 | Thompson Peter A. | director | Acquired · Option exercise | 30,000 | $15.00 | ↗ |
| Jan 28, 2026 | Thompson Peter A. | director | Acquired · Option exercise | 15,000 | $9.70 | ↗ |
| Jan 28, 2026 | Thompson Peter A. | director | Acquired · Option exercise | 15,000 | $12.50 | ↗ |
| Jan 28, 2026 | Thompson Peter A. | director | Acquired · Option exercise | 15,000 | $3.61 | ↗ |
| Jan 28, 2026 | Thompson Peter A. | director | Acquired · Option exercise | 15,000 | $2.00 | ↗ |
| Jan 28, 2026 | Thompson Peter A. | director | Acquired · Option exercise | 15,000 | $3.27 | ↗ |
| Jan 28, 2026 | Thompson Peter A. | director | Acquired · Option exercise | 15,000 | $2.74 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Corvus Pharmaceuticals do institutions hold?
13F filers reported holding 83.9% of Corvus Pharmaceuticals' shares as of Sep 30, 2026, across 175 filers.
How many 13F filers hold Corvus Pharmaceuticals?
Corvus Pharmaceuticals was held by 175 13F filers as of Sep 30, 2026.
Not investment advice.

